New Chantix scrips drop by almost half

Talk about an image being worth a thousand words. A Wall Street Journal chart tracking new Chantix prescriptions since January shows the kind of downward slope you only want to see on a double black diamond ski run. From close to 150,000 per week, the numbers have dropped to a point just north of 85,000. That's gotta hurt at Pfizer, which had counted the stop-smoking med among its few recent success stories.

Can Pfizer turn the Chantix tide? It launched a PR campaign last week, highlighting the undeniable fact that more than 6 million people have now taken the drug, and while some of its side effects can be severe--it's been blamed for suicides, accidents, and more--smoking itself has deadly side effects, and they're a lot more prevalent, percentage-wise, than adverse events related to Chantix. Even docs who've slowed down on firing off Chantix scrips tell the WSJ Health Blog that the fall--off is "fear-driven--not science-driven."

- see the Health Blog post

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.